DE60019318D1 - Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe - Google Patents

Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Info

Publication number
DE60019318D1
DE60019318D1 DE60019318T DE60019318T DE60019318D1 DE 60019318 D1 DE60019318 D1 DE 60019318D1 DE 60019318 T DE60019318 T DE 60019318T DE 60019318 T DE60019318 T DE 60019318T DE 60019318 D1 DE60019318 D1 DE 60019318D1
Authority
DE
Germany
Prior art keywords
methods
compositions
dna damaging
sensitization
transition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019318T
Other languages
English (en)
Other versions
DE60019318T2 (de
Inventor
Masashi Suganuma
Takumi Kawabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbas Co Ltd
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP26939899A external-priority patent/JP2001086991A/ja
Priority claimed from JP34032299A external-priority patent/JP2001157585A/ja
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Application granted granted Critical
Publication of DE60019318D1 publication Critical patent/DE60019318D1/de
Publication of DE60019318T2 publication Critical patent/DE60019318T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE60019318T 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe Expired - Lifetime DE60019318T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP26939899A JP2001086991A (ja) 1999-09-22 1999-09-22 オリゴペプチド
JP26939899 1999-09-22
JP34032299 1999-11-30
JP34032299A JP2001157585A (ja) 1999-11-30 1999-11-30 抗癌療法の増強剤とそのスクリーニング方法
PCT/IB2000/001438 WO2001021771A2 (en) 1999-09-22 2000-09-21 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents

Publications (2)

Publication Number Publication Date
DE60019318D1 true DE60019318D1 (de) 2005-05-12
DE60019318T2 DE60019318T2 (de) 2006-03-09

Family

ID=26548750

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019318T Expired - Lifetime DE60019318T2 (de) 1999-09-22 2000-09-21 Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe

Country Status (11)

Country Link
US (2) US6881575B1 (de)
EP (1) EP1218494B1 (de)
JP (1) JP4610828B2 (de)
AT (1) ATE292677T1 (de)
AU (1) AU7548500A (de)
CA (1) CA2385257A1 (de)
DE (1) DE60019318T2 (de)
DK (1) DK1218494T3 (de)
ES (1) ES2239037T3 (de)
PT (1) PT1218494E (de)
WO (1) WO2001021771A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003052483A1 (fr) 2001-12-17 2003-06-26 Olympus Corporation Systeme de microscope
ES2311703T3 (es) * 2002-01-17 2009-02-16 Takeda Pharmaceutical Company Limited Peptidos y peptidomimeticos que tienen actividad anti-proliferativa y/o que aumentan agentes o tratamientos que dañan los acidos nucleicos.
ES2329778T3 (es) 2002-01-18 2009-12-01 Novozymes A/S 2,3-aminomutasa de alanina.
JP4919598B2 (ja) 2002-06-06 2012-04-18 株式会社 キャンバス Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物
AU2004203977B2 (en) 2003-01-09 2010-06-17 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
US7125842B2 (en) * 2003-04-07 2006-10-24 Canbas Co. Ltd. Anti-fungal compounds and methods of use
WO2004093873A1 (en) 2003-04-17 2004-11-04 Janssen Pharmaceutica, N.V. 2-phenyl-benzimidazol and 2-phenyl-imidazo-`4,5!-pyridine derivatives as checkpoint kinase cds1 (chk2) inhibitors for the treatment of cancer
WO2004106924A2 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab Testing cell cycle regulation effect of a compound using a hollow fibre cell implant
CA2530900A1 (en) 2003-06-25 2004-12-29 Canbas Co., Ltd. Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity
JP2007501608A (ja) * 2003-08-08 2007-02-01 株式会社 キャンバス 抗癌治療の効力を推定するための感受性試験
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
MXPA06003110A (es) * 2003-09-17 2006-06-20 Icos Corp Uso de inhibidores de chk1 para controlar la proliferacion celular.
US7250427B2 (en) 2004-06-30 2007-07-31 Janssen Pharmaceutica, N.V. Aryl-substituted benzimidazole and imidazopyridine ethers
CN105175394B (zh) 2007-04-11 2018-06-08 三井有限公司 具有抗癌活性的化合物
WO2008140724A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
CN102149725A (zh) * 2008-05-14 2011-08-10 三井有限公司 用于抑制g2细胞周期停滞和使细胞对dna损伤剂敏感的cbp501衍生制剂及基于其的方法
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
WO2017143397A1 (en) * 2016-02-23 2017-08-31 Monash University INHIBITORS OF β-ARRESTIN-NEUROKININ 1 RECEPTOR INTERACTIONS FOR THE TREATMENT OF PAIN
CN114470178A (zh) * 2019-12-05 2022-05-13 王连生 一种促进心肌再生的重组人chk1蛋白激酶水凝胶及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443962A (en) * 1993-06-04 1995-08-22 Mitotix, Inc. Methods of identifying inhibitors of cdc25 phosphatase
AU6014998A (en) * 1997-01-13 1998-08-03 Pharmacia & Upjohn Company Special catalytic domains of cdc25c phosphatase

Also Published As

Publication number Publication date
CA2385257A1 (en) 2001-03-29
JP2003518368A (ja) 2003-06-10
US6881575B1 (en) 2005-04-19
DK1218494T3 (da) 2005-08-08
EP1218494B1 (de) 2005-04-06
ATE292677T1 (de) 2005-04-15
ES2239037T3 (es) 2005-09-16
US7851592B2 (en) 2010-12-14
PT1218494E (pt) 2005-08-31
DE60019318T2 (de) 2006-03-09
JP4610828B2 (ja) 2011-01-12
WO2001021771A2 (en) 2001-03-29
EP1218494A2 (de) 2002-07-03
US20050059116A1 (en) 2005-03-17
AU7548500A (en) 2001-04-24
WO2001021771A3 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
DE60019318D1 (de) Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2005030121A3 (en) Compounds, compositions and methods
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE511503T1 (de) Aryl- und heteroarylharnstoff-chk1-inhibitoren zur verwendung als radiosensibilisatoren und chemosensibilisatoren
DE60029799D1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
ATE482213T1 (de) Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO20061194L (no) Mitotiske kinesininbibitorer
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
AU2005253776A8 (en) Screening methods using c-Abl, Fyn and Syk in combination with tau protein
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
WO2004085418A3 (en) Xanthones, thioxanthones and acridinones as dna-pk inhibitors
ATE473728T1 (de) Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
NO20055517L (no) 4-,6-O 7-hydroksyindoler med N-oksidgrupper og anvendelse av disse som terapeutiske midler
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
EP1511713B8 (de) Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna-schädigenden behandlungen erhöhen
WO2005032595A3 (en) Methods and compositions for the inhibition of stat5 in prostate cancer cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition